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Surgical site infections (SSIs) of groin wounds are a common and potentially
preventable cause of morbidity, mortality, and healthcare costs in vascular
surgery. Our aim was to define the contemporaneous rate of groin SSIs,
determine clinical sequelae, and identify risk factors for SSI.
An international multicentre prospective observational cohort study of consec-
utive patients undergoing groin incision for femoral vessel access in vascular
surgery was undertaken over 3 months, follow-up was 90 days. The primary
outcome was the incidence of groin wound SSI.
1337 groin incisions (1039 patients) from 37 centres were included. 115 groin
incisions (8.6%) developed SSI, of which 62 (4.6%) were superficial. Patients
who developed an SSI had a significantly longer length of hospital stay (6 ver-
sus 5 days, P = .005), a significantly higher rate of post-operative acute kidney
injury (19.6% versus 11.7%, P = .018), with no significant difference in 90-day
mortality. Female sex, Body mass index≥30 kg/m2, ischaemic heart disease,
aqueous betadine skin preparation, bypass/patch use (vein, xenograft, or pros-
thetic), and increased operative time were independent predictors of SSI.
Groin infections, which are clinically apparent to the treating vascular unit,
are frequent and their development carries significant clinical sequelae. Risk




Surgical site infections (SSIs) are the most common type
of healthcare-associated infections worldwide, complicat-
ing up to one-third of surgical procedures,1 and varying
between countries and specialties.1,2 SSIs increase
healthcare costs and represents a significant cause of pre-
ventable morbidity and death.3,4 SSIs after vascular inter-
vention are potentially catastrophic, with prosthetic graft
infection generally mandating the explanation of infected
material. This carries a risk of limb loss and death, there-
fore, research into their occurrence and prevention has
been the focus of recently published guidelines.5
Groin incisions allow access to the femoral vessels
and are the most frequently performed surgical exposures
in vascular surgery. Proximity to the anal canal, external
genitalia, and the presence of skin folds result in difficul-
ties in local decontamination. Furthermore, patients
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frequently suffer comorbidities such as diabetes mellitus,
renal impairment, and malnutrition, which are indepen-
dent risk factors for SSI development.6-8 Published groin
SSI rates varies considerably, ranging from 6.4% to
38.5%9-12; however, these studies are generally small, ret-
rospective, or use heterogeneous definitions of SSI.7,11
The National Institute for Health and Care Excellence
(NICE) guidelines regarding the prevention and treat-
ment of SSI recommend preoperative, intraoperative, and
postoperative strategies.13 In addition, relatively novel
interventions and adjuncts have been developed for clini-
cal use aiming to reduce SSIs, including antimicrobial
wound products,14 bacteria-binding dressings,15 or closed
incision negative pressure wound therapy.16,17 It is
unknown whether vascular units follow NICE guidelines,
or how frequently wound adjuncts are used.
The Groin wound Infection after Vascular Exposure
(GIVE) study's primary aim was to determine the con-
temporaneous incidence of groin wound SSI in vascular
patients. Secondary aims were to identify the clinical
sequelae for those who developed an SSI and identify risk
factors for SSI in this patient population.
2 | METHODS
A detailed study protocol has been published in full.18 An
abridged protocol was circulated to all centres prior to
starting (Supplementary Material 1).
2.1 | Study design and setting
GIVE was an international multicentre prospective obser-
vational cohort study of patients undergoing groin incision
for access to the femoral arteries during vascular surgery.
GIVE was designed and run by the Vascular and Endo-
vascular Research Network (VERN; https://vascular-
research.net/), a multidisciplinary trainee-led vascular
research collaborative,19 with a track record for delivering
on multicentre research projects.20-24 The study was con-
ducted in hospitals providing emergency and/or elective
vascular surgery. Invitations to participate were dissemi-
nated by VERN using social media, email, and personal
contacts.
The study opened to site set up on January 21, 2019,
and closed to site recruitment on 01/05/2019. Each
centre's designated study lead determined an appropriate
start date. Centre’s undertook a three-month period of
data collection, followed by 3 months of patient follow up.
The study was considered complete at centres when
the last recruited patient completed follow up. Follow-up
was complete for all centres by 01/11/2019.
2.2 | Population, recruitment,
and inclusion/exclusion criteria
Potential participants were identified by the local study
team in each centre by a screening of local theatre man-
agement systems. Patients were deemed eligible for inclu-
sion if they were aged >18, undergoing emergency/
urgent/elective groin incision(s) for arterial intervention,
including endarterectomy, embolectomy, thrombectomy,
bypass, repair of (non-infected) traumatic injury
(e.g. iatrogenic arterial pseudoaneurysm), or exposure for
an endovascular procedure. Groin incisions that extended
down the leg or above the groin were included; however,
SSI outcomes were based on the portion of the wound
overlying the femoral triangle. In bilateral cases, both
sides were included in data capture. Participants were
excluded if undergoing groin incision for an active
infected process (e.g. infected pseudoaneurysm), venous
access only, arterial exposure for cardiac procedures, and
percutaneous only procedures.
2.3 | Data collection, management,
and validation
A data collection pro forma was designed and refined by
the VERN committee (Supplementary Material 2). Explan-
atory variables were selected based on published work on
SSIs, clinical relevance, and mechanistic plausibility.
Key Messages
• the GIVE Multicentre Cohort Study is one of
the largest non-registry prospective cohort
study to examine groin SSIs among vascular
patients
• while it is well documented that SSIs are the
cause of significant morbidity for patients
undergoing arterial exposure of the groin, a
contemporaneous incidence, and the resultant
sequelae, have not been established
• we identified an incidence of clinically relevant
groin wound SSIs of 8.6%
• female sex, BMI≥30 kg/m2, ischaemic heart
disease, aqueous betadine skin preparation,
bypass/patch use (vein, xenograft, or pros-
thetic), and increased operative time predicted
for increased SSI risk.
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Definitions of co-morbidities and specific outcomes are
given in Supplementary Material 3. Data were collected
prospectively and held electronically on a single secure
hospital computer, in accordance with local guidelines.
Study participants were pseudonymised at the local centre.
Pseudonymised data were uploaded via a web-based inter-
face or sent via a secure National Health Service (NHS)
email. Data were collected, stored, and analysed in the
Aneurin Bevan University Health Board, Newport, UK,
following local Caldicott guardian approval.
Data points recorded as “unknown” counted as com-
plete data. However, any patient with missing data
(i.e. data entry absent) of >5% was returned to the team
for further data extraction, or (if unable) the record was
removed from the analysis. To examine data accuracy, a
smaller subset of centres underwent a review of >5% of
their data points by an independent data extractor. The
accuracy of data extraction was examined by comparing
the original and re-extracted data. A priori it was decided
that an accuracy of <95% would prompt a review of the
entire centre's data collection.
2.4 | Team organisation
Each centre organised a team of healthcare professionals
who would gain local audit approval (or ethical approval),
identify suitable patients, and capture data. Teams would
typically include a single senior team member (consultant
or equivalent), who would act as a local Principal Investi-
gator (PI). A detailed authorship policy, developed in
accordance with the International Committee of Medical
Journal Editors (ICMJE) authorship guidelines, was pro-
vided in the GIVE protocol (Supplementary material 1).
2.5 | Outcomes
The primary outcome was the development of a groin
wound SSI, defined according to the 2019 Centre for Disease
Control (CDC) criteria.25 Superficial infections presenting
within 30 days of surgery, and deep/organ/space infections
presenting within 90 days of surgery, within the femoral tri-
angle of the index groin, were considered SSIs. SSIs apparent
to the secondary care vascular team were identified from
local hospital electronic records and notes; patients were not
contacted directly to obtain outcome data. In the case of
uncertainty, the view of the local PI was sought.
Secondary outcomes were:
1. Incidence of deep tissue/organ SSI;
2. Incidence of surgical and radiological re-interven-
tions used to manage SSI;
3. Incidence of SSI resulting in sepsis;
4. Incidence of SSI resulting in unplanned admission to
a critical care setting;
5. Incidence of post-operative acute kidney injury
(AKI);
6. Length of stay (LOS) in hospital;
7. Mortality;
8. Incidence of additional dressings used to man-
age SSI;
9. Incidence of vacuum dressings used to manage SSI;
10. Incidence of antibiotics used to manage SSI; and
11. Organisms grown from microbiology samples.
2.6 | Statistical analysis
Results are reported as per the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) state-
ment for observational studies.26 Continuous variables
were analysed using parametric or non-parametric tests as
appropriate. Percentages were calculated using the total
number of patients (for patient-specific variables) or the
total number of groins (for operative and post-operative
variables and outcomes) as a denominator as appropriate.
SSI rates from individual centres were presented as funnel
plots using a Microsoft Excel macro.27
Multiple imputation was undertaken using the Mar-
kov chain Monte Carlo method (25 imputed data sets;
25 iterations) prior to univariate and multivariate binary
logistic analysis of predictors of all SSIs. A sensitivity
analysis without multiple imputation (casewise deletion)
was performed, using univariate and multivariate multi-
level binary logistic regression analysis. Further analyses
examining predictors of deep/organ/space SSIs, regres-
sion for UK and Ireland patients only, and regression
excluding centres with an SSI rate above three standard
deviations were also undertaken. For all analyses, univar-
iate regression was undertaken using a threshold of
P < .10. Significant variables were subsequently included
in a backward stepwise multivariate regression, with sta-
tistical significance defined as P < .05. Data were
analysed in SPSS (IBM, New York, version 24).
2.7 | Local audit and ethical approval
For UK centres, the study did not require approval from
an NHS Research Ethics Committee as per guidance by
the Healthcare Research Authority (HRA) and NHS
Good Clinical Practice (GCP) principles. The study was
registered locally at each participating centre prior to
data collection (audit and service provision registration at
all NHS sites involved). Those centres outwith the United
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ratio 95% CI P value
All cases 115 (8.6) 1222 (91.4)
Outside of United Kingdom 7 (6.1) 154 (12.6) 0.449 0.205-0.983 .045*
Age 72 (65-79) 71 (64-77) 1.015 0.996-1.034 .116
Sex-Female 39 (33.9) 297 (24.3) 1.598 1.063-2.402 .024*
Emergency 41 (35.7) 494 (40.6) 0.811 0.544-1.207 .302
Rutherford-(0-3) 51 (45.9) 575 (48.8) Reference
Rutherford-(4-6) 60 (54.1) 603 (51.2) 1.117 0.760-1.643 .573
Body mass index-normal weight (18.5-24.9 kg/m2) 18 (25.0) 326 (41.1) Reference
Body mass index-underweight (<18.5 kg/m2) 5 (6.9) 26 (3.3) 2.104 1.020-4.341 .044*
Body mass index-Overweight (25-29.9 kg/m2) 15 (20.8) 262 (33.0) 1.164 0.603-2.246 .650
Body mass index - Obese (≥30 kg/m2) 34 (47.2) 180 (22.7) 2.527 1.365-4.678 .003*
Diabetes (any) 44 (38.6) 322 (26.5) 1.74 1.169-2.591 .006*
Alcohol excess 12 (11.3) 104 (9.6) 1.271 0.677-2.387 .455
eGFR <30 mL/min/1.73 m2 8 (8.6) 45 (4.2) 2.142 0.986-4.652 .054*
Hypertension 88 (77.2) 896 (73.3) 1.194 0.758-1.879 .445
Congestive cardiac failure 13 (34.2) 127 (10.5) 1.128 0.615-2.071 .697
Chronic obstructive pulmonary disease 39 (34.2) 266 (22.0) 1.835 1.218-2.765 .004*
Ischaemic heart disease 58 (51.8) 376 (31.5) 2.250 1.526-3.319 <.001*
Hyperlipidaemia 54 (51.9) 545 (50.5) 1.116 0.749-1.662 .590
Neurological disease 17 (14.9) 182 (15.0) 0.984 0.574-1.688 .954
Immunomodulators 5 (4.3) 58 (4.8) 0.901 0.354-2.294 .826
Previous SSI 6 (5.3) 38 (3.2) 1.75 0.736-4.162 .205
Bilateral groin incisions 36 (31.3) 560 (45.8) 0.539 0.358-0.812 .003*
American Society of Anaesthesiologists
classification - 1-2
21 (19.4) 229 (19.6) Reference
American Society of Anaesthesiologists
classification - 3-5
87 (80.6) 937 (80.4) 1.067 0.649-1.754 .797
Open wound on lower limb(s) 31 (27.0) 282 (23.3) 1.202 0.780-1.853 .405
Re-do groin incision 23 (20.2) 199 (16.5) 1.277 0.788-2.068 .320
Antibiotic prophylaxis (any) 110 (99.1) 1166 (98.9) 1.200 0.218-6.609 .833
Pre-operative hair removal with clippers 96 (92.3) 1042 (92.3) 0.896 0.442-1.817 .761
Skin prep - Alcoholic chlorhexidine 52 (52.5) 608 (55.1) Reference
Skin prep - Aqueous chlorhexidine 5 (5.1) 79 (7.2) 0.763 0.294-1.977 .577
Skin prep - Alcoholic betadine 19 (19.2) 301 (27.3) 0.788 0.458-1.354 .388
Skin prep - Aqueous betadine 23 (23.2) 110 (10.0) 2.303 1.342-3.953 .002*
Skin prep - Two solutions 0 5 (0.5) 1.376 0.440-4.302 .581
Adhesive skin prep - None 12 (12.1) 117 (10.8) Reference
Adhesive skin prep - Iodinated 71 (71.7) 830 (76.3) 0.803 0.433-1.490 .487
Adhesive skin prep - Non-iodinated 16 (16.2) 141 (13.0) 1.089 0.501-2.366 .830
Longitudinal groin incision 97 (85.1) 935 (78.0) Reference
Oblique groin incision 17 (14.9) 263 (22.0) 0.607 0.356-1.035 .066*
Abdominal/leg incisions - None 72 (64.3) 803 (67.0) Reference
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Kingdom were compliant with local regulations prior to




A total of 37 centres participated in GIVE, 30 of which
were within the United Kingdom, 1 from Greece, 1 from
Ireland, 2 from Australia, and 3 from Libya. 25 patients
were excluded from analysis due to unacceptable levels of
missing data (>5%) or insufficient follow up data. Data
originating from Libya were excluded from analyses, as
data capture was delayed due to a civil war. 1039 patients
(938 from the United Kingdom) were included in the final
analysis. 298 patients (28.7%) had bilateral groin incisions
resulting in 1337 groin incisions in total (1176 UK groin
incisions). Centres reported data on a median of 30 patients
(range 5–92; 40 groin incisions, range: 6–111). The centres
participating in data validation had >95% accuracy.
Baseline demographic details are given in Table 1.










ratio 95% CI P value
Abdominal/leg incisions -
Separate abdominal incision
12 (10.7) 125 (10.4) 1.032 0.545-1.954 .923
Abdominal/leg incisions - Groin incision extended to
leg
5 (4.5) 65 (5.4) 0.855 0.339-2.159 .741
Abdominal/leg incisions - Separate leg incision 23 (20.5) 206 (17.2) 1.223 0.747-2.002 .423
Open procedure only 74 (64.3) 724 (59.3) Reference
Aneurysmal endovascular procedure +/− open
procedure
10 (8.7) 273 (22.4) 0.356 0.181-0.698 .003*
Occlusive endovascular procedure +/− open
procedure
31 (27.0) 225 (18.5) 1.339 0.858-2.090 .198
Bypass/patch material-None 12 (10.6) 369 (31.2) Reference
Bypass/patch material-Vein 28 (24.8) 281 (23.7) 3.109 1.556-6.212 .001*
Bypass/patch material - Xenograft 37 (32.7) 202 (17.1) 5.513 2.817-10.788 <.001*
Bypass/patch material-Prosthetic 36 (31.9) 332 (28.0) 3.274 1.679-6.382 <.001*
Muscle flap used 1 (0.9) 9 (0.7) 1.280 0.185-8.875 .802
Drain(s) used 55 (48.2) 418 (34.7) 1.784 1.213-2.623 .003*
Local antibiotic use 12 (10.8) 172 (14.4) 0.754 0.410-1.387 .363
Closure-subcuticular suture 88 (77.2) 902 (75.3) Reference
Closure-skin clips 16 (14.0) 223 (18.6) 0.744 0.428-1.294 .295
Closure-external suture 10 (8.8) 73 (6.1) 1.349 0.670-2.714 .402
Dressing-absorbent adhesive 95 (84.1) 1020 (85.8) Reference
Dressing-skin glue only 8 (7.1) 125 (10.5) 0.685 0.325-1.445 .321
Dressing-closed incision negative pressure therapy 9 (8.0) 41 (3.4) 2.372 1.123-5.011 .024*
Dressing-open wound negative pressure therapy 1 (0.9) 3 (0.3) 1.061 0.161-6.992 .951
Operative time (hours) 3.3 (2.5-4.5) 3.0 (2.0-4.0) 1.181 1.064-1.310 .002*
Estimated blood loss (L) 0.255
(0.200-0.500)
0.250 (0.100-0.500) 1.144 0.838-1.561 .397
Intraoperative glycaemic control 19 (19.2) 160 (14.2) 1.476 0.896-2.430 .126
Intraoperative transfusion 15 (15.6) 101 (9.4) 1.708 0.985-2.961 .057*
Laminar flow theatre 54 (48.2) 556 (47.2) 1.049 0.713-1.543 .807
*Statistically significant.
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71 years (Interquartile range (IQR) 64–77). The median
body mass index (BMI) was 26 kg/m2 (IQR 23 - 30 kg/
m2). 311 patients (30.1%) had diabetes (any type). 814
(82.2%) were American Society of Anaesthesiologists
(ASA) physical status 3–5, and 447 (43.2%) underwent an
urgent or emergency procedure.
3.2 | Operative Interventions
and post-operative outcomes
A total of 1032 (78.7%) incisions were longitudinal (ver-
sus oblique) and 222 (16.8%) were “re-do” incisions.
Operations were classified into one of three groups:
“open” procedure only, which included any arterial sur-
gery requiring groin exposure without endovascular
intervention, comprised 798 (59.7%) of operations; “aneu-
rysmal endovascular” procedures, involving groin access
(+/− groin intervention) for an endovascular aorto-iliac
aneurysmal repair, comprised 283 (21.2%) operations;
and “occlusive endovascular” procedures, involving groin
access (+/− groin intervention) for endovascular aorto-
iliac/infra-inguinal occlusive disease, comprised
256 (19.1%) operations. SSIs occurred in 74 (9.3%) “open
procedure only” cases (reference), 10 (3.5%) “aneurysmal
endovascular procedure +/- groin intervention” cases
(OR 0.492, P = .018), and 31 (12.1%) “occlusive endo-
vascular procedure +/- groin intervention” cases (OR
1.306, P = .237). In the group of patients that developed
an SSI, patients who underwent an endovascular proce-
dure (either for aneurysmal or occlusive disease) were
significantly more likely to develop post-operative AKI
compared to those who did not (10 (15.6%) versus 13
(46.4%), P = .019). This difference was not observed in
the group who did not develop SSI.
Antibiotic prophylaxis was given in 1276 (98.9%) inci-
sions. 1138 (92.3%) had pre-operative hair removal with
clippers. The most commonly used skin preparation solu-
tion was alcoholic chlorhexidine (660 groins; 54.9%); an
iodinated adhesive skin drape was used in 901 groins
(75.9%). Local antibiotics (e.g. Collatamp®) were used in
184 groins (14.1%). The most common method of skin
closure was a continuous subcuticular suture (990 groins;
75.5%). The most common dressing type used was absor-
bent adhesive (1115 groins; 85.6%). Closed incision nega-
tive pressure therapy was used in 50 groins (3.8%).
Median (IQR) operative time and estimated blood loss
(EBL) were 3 hours (2–4) and 0.250 L (0.125–0.500),
respectively.
A total of 54 (5.2%) patients died within 90 days of
surgery. The median LOS was 5 days (IQR 3–10).
128 patients (12.4%) developed a post-operative AKI.
3.3 | Surgical site infection rates
A total of 107 patients (10.3%) developed 115 SSIs
(Figure 1), which equates to a rate of 8.6% per groin inci-
sion (Figure 2). 62 (4.6%) groin SSIs were superficial,
51 (3.8%) were deep/organ/space infections (Figure 3). A
pus swab or tissue sample was sent for microbiological
analysis in 83 (76.1%) of SSIs. The most commonly found
organisms were coliforms (72.3%). Details of the microor-
ganisms grown are given in Table 2.
SSIs resulted in sepsis in 17 patients (1.6%). 50 (3.7%)
groins required further surgical or radiological interven-
tion, 37 of which (2.77%) required management of
infected fluid/tissue, and 13 (0.97%) required explanta-
tion of foreign material. Limb loss occurred as a result of
SSIs in four cases (0.30%). Other outcomes are shown in
Table 2.
Patients who developed an SSI had a significantly lon-
ger median LOS (6 versus 5 days; P = .005), and a signifi-
cantly higher rate of post-operative AKI (19.6% versus
11.7%; P = .018). There was no significant difference in
90-day mortality rate (8.4% versus 4.9%; P = .114). Sensi-
tivity analysis of LOS excluding patients who underwent
an amputation as a result of SSI (N = 4) produced consis-
tent results; patients who developed an SSI had a signifi-
cantly longer median LOS (6 versus 5 days; P = .005).
3.4 | Regression analysis
Multiple imputation was undertaken as described above.
Details of unknown/missing data per variable are given in
Supplementary Material 4. A comparison of patient and
operative factors between those who did and did not
develop an SSI is shown in Table 1. Significant predictors
of SSI on univariate analysis are given in Table 1. Details
of which antibiotic agents were used as prophylaxis were
captured and each agent subjected to univariate analysis,
none were identified as significant predictors for SSI. The
variables remaining significant in multivariate analysis
include female sex, BMI ≥30 kg/m2, ischaemic heart dis-
ease (IHD), aqueous betadine skin preparation, use of
bypass/patch material (vein, prosthetic, or xenograft), and
increased operative time (Table 3). Sensitivity analysis
with case-wise deletion resulted in a broadly similar model
(Supplementary Material 5). A further regression analysis
of significant variables predicting deep/organ/space SSIs is
given in Supplementary Material 6. A sensitivity analysis
only including patients from the UK and Ireland is shown
in Supplementary Material 7. Sensitivity analysis excluding
centres with an SSI rate above three standard deviations is
shown in Supplementary Material 8.
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4 | DISCUSSION
This contemporary, international, multicentre, cohort
study has found that the incidence of all SSIs in 1337
groin incisions was 8.6% with deep/organ/space SSIs
being 3.8%. Patients who developed an SSI had a signifi-
cantly increased LOS and incidence of AKI and had a
non-significant greater 90-day mortality. Further
FIGURE 2 Funnel plot of SSI rates
of each centre, with +/−2 and +/−3 SD
lines
FIGURE 1 Flow diagram of patient recruitment and outcomes
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interventions were required in 43.6% of patients who
developed an SSI. A BMI of ≥30 kg/m2, aqueous betadine
skin preparation and the use of xenograft significantly
increased the risk of developing an SSI threefold. The use
of prosthetic material (either for patch or bypass), IHD,
and longer operative time also increased the risk of SSI.
Sensitivity regression analyses including UK and Ireland
patients only, and excluding centres with an SSI rate
above three standard deviations produced similar results
indicating a stable model.
The majority of published literature regarding groin
SSIs have been small,28 from single centres,10,11 histori-
cal, reliant on national registry data,7,28 use varying defi-
nitions of SSI29 and are retrospective.28 This has made it
difficult to benchmark practice and provide estimates to
inform the design of future randomised trials. This study
provides valuable and robust data on groin SSI rates and
outcomes. The increase in LOS and AKI is consistent
with the previous studies.7 However, confounding could
account for these findings, further analysis of the SSI
group revealed that a significantly higher proportion of
patients who underwent an endovascular procedure
developed post-operative AKI, compared to those who
did not. Sensitivity analysis excluding patients who
underwent an amputation as a result of SSI was consis-
tent with the main analysis, however, it is unknown
whether these amputations were performed during the
same hospital admission. Some additional post-operative
events that may increase LOS were not captured in the
study introducing further potential confounding.
Multivariate analysis identified numerous indepen-
dent predictors for SSI development. Aqueous betadine is
the fourth choice of surgical skin preparation rec-
ommended by NICE guidance,13 with alcoholic chlorhex-
idine preferred over other preparations.13 Aqueous
betadine was used in 133 (11.1%) of all groins, its replace-
ment with aqueous chlorhexidine may represent the most
easily attainable change in practice for clinical benefit.
Obesity and morbid obesity have been well
described as risk factors for the development of SSI.30,31
Patients with a BMI of >30 kg/m2 were more than
three times more likely to develop an SSI postopera-
tively. Alternative access may be considered, such as
exposure of the superficial femoral artery with an inci-
sion below the groin, or exposure of the external iliac
artery through an oblique lower abdominal incision,
although these do not provide access to the Profunda,
and are in practice infrequently used.
Xenograft material use was associated with increased
SSI risk. The use of bovine pericardium has been exten-
sively investigated in the context of carotid endarterec-
tomy (CEA) and was found to have no association with
SSI development.32 These findings seemingly cannot be
extrapolated to groin incisions. There are intrinsic biases,
which may account for this finding; prosthetic material is
less likely to be used in high-risk groins, greater wound
dissection is required for harvesting a vein, and prosthetic
grafts may present with late infection. While autologous
tissues are generally preferred, the harvest of autologous
vein for arteriotomy patch-plasty will affect future con-
duit availability.
Female sex was an independent predictor of both all
SSIs, and deep/organ/space SSI, consistent with findings
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FIGURE 3 Funnel plot of deep
and organ/space SSI rates of each
centre, with +/−2 and +/− 3 SD lines
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cohorts.33,34 A potential reason for this finding is the dif-
ference in fat distribution between genders, and differ-
ences in groin skin flora.
Coliforms were the most frequently isolated organ-
isms from groins, which developed an SSI, 6% of which
were multidrug-resistant. In contrast, a previous US
observational study reported that the most commonly
isolated organism was staphylococcus followed by coli-
forms.28 This may represent a difference in microbiome
between UK and US populations, or antibiotic prophy-
laxis regimes, which predominantly cover skin organ-
isms. Alternatively, this may be indicative of the fact that
more superficial SSIs, of which the majority would be
Staphylococcal, may have been treated in the community
and not identified in this study. None of the antibiotic
agents used in the study were significant predictors on
univariate analysis.
This study has several strengths. It utilised the well-
established trainee-led collaborative model to collect
prospective data on a large number of patients from
the many UK and international centres without
funding, expediting the process and producing up-to-
date results. It addresses a pertinent clinically relevant
issue; the importance of SSIs have been highlighted in
a recently completed UK Vascular Surgery Delphi exer-
cise.35 To the best of our knowledge, this represents the
largest prospective study of SSI rates after groin inci-
sion. Missing data are minimal and internal validation
was reported at 95% accuracy. Sensitivity analyses were
consistent, with minimal changes to variable effects,
implying that the process of multiple imputation was
robust.
As with any observational study, there are a number
of limitations. In order to avoid the need for UK ethical
approval, the GIVE study team made the pragmatic deci-
sion to only record SSIs that became evident to the index
vascular centre. Milder community treated SSIs, or SSIs
treated at a different centre, will have been missed, intro-
ducing bias to our results. The true incidence of SSIs will
likely be higher than reported here, however, the rate of
deep/organ/space SSIs reported is likely to be true and is
similar to the published literature.36 The data is self-
reported by the treating teams and has not been exter-
nally validated, potentially limiting reliability. Centres
TABLE 2 Outcomes of SSI development
SSI specific outcomes
Variable # Valid %
Grade of SSI (per groin incision)
Superficial SSI 62 4.6
Deep SSI 44 3.3
Organ or space SSI 7 0.5
Interventions for SSI (per groin incision)
Additional dressings used to manage SSI 83 6.2
Vacuum dressings used to manage SSI 27 2.0
Antibiotics used to manage SSI 107 8.0
SSI required radiological or surgical intervention 37 2.8
SSI required explantation of foreign material 13 1.0
Microbiology (per groin incision)
Swab/pus/fluid/tissue/foreign material sent for microbiological analysis 83 6.2
Culture result-No organism grown 12 0.9
Culture result-Skin commensals 11 0.8
Culture result-Staphylococcus aureus 13 1.0
Culture result-Streptococci 4 0.3
Culture result–Coliforms 60 4.5
Culture result-Methicillin Resistant Staphylococcus Aureus (MRSA) 1 0.1
Culture result-Vancomycin resistant enterococcus (VRE) 4 0.3
Clinical outcomes of SSI (per patient)
SSI resulting in sepsis 17 1.6
SSI resulting in additional or unexpected HDU/ITU stay 8 0.8
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were provided with criteria for SSI diagnosis; however,
there was no independent wound assessment. Some vari-
ables, for example, anaemia,28 and smoking,8 were not
collected. We were, therefore, unable to account for
potential confounding from these variables, limiting the
accuracy of our multivariate analysis results. Variables
such as BMI had many missing data. Multiple imputation
of missing values was undertaken, with sensitivity ana-
lyses being concordant with results from multiple impu-
tation; however, this method remains inferior to
obtaining actual data on all patients. Although the associ-
ation has been demonstrated by the analyses, causation
cannot be inferred without randomised data. Lastly, over
90% of the data originated from the UK, limiting interna-
tional generalisability.
SSI remains a significant problem in vascular surgery
and there is an inherent need to improve practice and to
evaluate aspects of SSI prevention with high quality
randomised studies or registry data. There are a number
of interventions that require further evaluation and
are yet to enter everyday clinical practice. GIVE has
benchmarked SSI rates and provides a platform for future
randomised trials in SSI prevention.
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